TEST:

Oncomine™ TCR Beta-LR Assay

These results demonstrate that the TCR repertoire is associated with characteristics, genetic alterations, and clinical outcomes. Monitoring changes in the TCR repertoire may serve as a prognostic biomarker for breast cancer patients.

These data suggested that TCR repertoire is associated with clinicopathological characteristics including stage and recurrence. TCR clonal richness might provide prognostic value for patients receiving neoadjuvant chemotherapy.

RNA-based HTS- TRB can provide objective assessment of T-cell clones and could be useful for initial staging and disease monitoring in MF/SS.

The proportion of irAE-high (grade≥II) was positively related to number of TRBV genes and of uncommon V alleles in Chinese NSCLC patients, indicating that the profile of TRBV haplotype group 1 might predict higher risk to develop irAE-high during immunotherapy. These results could be helpful to stratify the subpopulation of Chinese NSCLC patients who have high risk to develop irAE. More robust studies with larger sample size will be needed to accumulate further supportive data.

Here, we performed TCR sequencing in patients from the phase 2 trial SAKK 16/14 undergoing neoadjuvant chemotherapy with three cycles of cisplatin / docetaxel followed by treatment with the PD-L1 antibody durvalumab. Our results show that TCR repertoire measured in peripheral blood samples and tumor tissue may provide a useful tool for predicting risk of recurrence after neoadjuvant sequential chemo-immunotherapy with durvalumab in patients with resectable stage IIIA (N2) NSCLC.